無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

C型肝炎:市場予測と分析

Disease Overview: Hepatitis C disease forecast and market analysis to 2035

発行 Datamonitor Healthcare 商品コード 365202
出版日 ページ情報 英文 618 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.65円で換算しております。
Back to Top
C型肝炎:市場予測と分析 Disease Overview: Hepatitis C disease forecast and market analysis to 2035
出版日: 2018年01月10日 ページ情報: 英文 618 Pages
概要

当レポートでは、C型肝炎治療薬市場について調査分析し、市場予測、治療、疫学、上市薬、パイプライン薬の動向など、体系的な情報を提供しています。

予測:C型肝炎

  • エグゼクティブサマリー
  • 市場概要・動向
  • 市場定義・調査手法
  • Daklinza (daclatasvir)
  • glecaprevir/pibrentasvir
  • Harvoni (sofosbuvir/ledipasvir)
  • Olysio (simeprevir)
  • sofosbuvir/velpatasvir
  • sofosbuvir/velpatasvir/GS-9857
  • Sovaldi (sofosbuvir)
  • Sunvepra (asunaprevir)
  • Technivie (paritaprevir/ritonavir/ombitasvir)
  • Viekira Pak (paritaprevir/ritonavir/ombitasvir + dasabuvir)
  • Zepatier (grazoprevir/elbasvir)
  • 1次調査手法

治療:C型肝炎

  • エグゼクティブサマリー
  • 1次調査手法
  • 疾患の定義・診断
  • 患者区分
  • 現在の治療オプション
  • 国別の治療系統
  • 処方動向
  • アンメットニーズ

疫学:米国・日本・EU5ヶ国のC型肝炎

  • エグゼクティブサマリー
  • 疾患の背景
  • 情報源・手法
  • 予測
  • 疫学者の考察
  • 強みと限界
  • 付録

上市薬:C型肝炎

  • エグゼクティブサマリー
  • 製品概要
  • 製品プロファイル:Daklinza
  • 製品プロファイル:Harvoni
  • 製品プロファイル:Olysio
  • 製品プロファイル:Sovaldi
  • 製品プロファイル:Sunvepra
  • 製品プロファイル:Viekira Pak
  • 製品プロファイル:Zepatier

価格と償還:C型肝炎

  • エグゼクティブサマリー
  • 市場の背景
  • 米国
  • 日本
  • EU5ヶ国

パイプライン:C型肝炎

  • エグゼクティブサマリー
  • 臨床パイプライン概要
  • 初期段階の機会
  • 製品プロファイル (後期段階) :DCV-TRIO
  • 製品プロファイル (開発後期) :glecaprevir/pibrentasvir
  • 製品プロファイル (開発後期) :sofosbuvir/velpatasvir/voxilaprevir
目次
Product Code: DMKC5260

Disease Overview

Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV). HCV belongs to the Flaviviridaevirus family, and is a communicable disease spread primarily through direct contact with the blood or the bodily fluids of an infected individual, including sexual and mother-to-child transmission. Hepatitis C infection normally does not produce signs or symptoms and, as such, most people who are infected do not know they have the disease.

Market Snapshot

Falling disease prevalence and anticipated price decreases as competition intensifies will drive a net decline in market value.

Harvoni remains the dominant option for GT-1/4 patients, but has ceded share to cheaper rivals as competition intensifies.

Cases are expected to decline, driven by complexities in high-risk populations, demographics, and treatment developments.

Mavyret's approval at a substantial discount to Epclusa paves the way for a further decline in Gilead's HCV revenues.

Lack of unmet need and declining market value prompts Johnson & Johnson and Merck & Co to discontinue pipeline regimens.

Pricing is the key differentiator for drugs in this market.

CONTENTS

12 FORECAST: HEPATITIS C (Published on 06 November 2017)

12 EXECUTIVE SUMMARY

13 MARKET DYNAMICS

20 FORECAST AND FUTURE TRENDS

37 MARKET DEFINITION AND METHODOLOGY

46 PRIMARY RESEARCH METHODOLOGY

48 BIBLIOGRAPHY

51 PRODUCT PROFILE: DAKLINZA

65 PRODUCT PROFILE: EPCLUSA

79 PRODUCT PROFILE: HARVONI

95 PRODUCT PROFILE: MAVYRET

112 PRODUCT PROFILE: SOVALDI

124 PRODUCT PROFILE: VIEKIRA PAK FRANCHISE

142 PRODUCT PROFILE: VOSEVI

156 PRODUCT PROFILE: XIMENCY

167 PRODUCT PROFILE: ZEPATIER

183 TREATMENT: HEPATITIS C (Published on 10 January 2018)

183 EXECUTIVE SUMMARY

185 PRIMARY RESEARCH METHODOLOGY

188 DISEASE DEFINITION AND DIAGNOSIS

196 PATIENT SEGMENTATION

206 CURRENT TREATMENT OPTIONS

213 PRESCRIBING TRENDS

228 UNMET NEEDS IN HEPATITIS C

231 EPIDEMIOLOGY: HEPATITIS C IN THE US, JAPAN, AND 5EU (Published on 08 November 2017)

231 EXECUTIVE SUMMARY

233 DISEASE OVERVIEW

235 SOURCES AND METHODOLOGY

246 FORECAST

259 EPIDEMIOLOGIST INSIGHT

262 STRENGTHS AND LIMITATIONS

265 BIBLIOGRAPHY

270 MARKETED DRUGS: HEPATITIS C (Published on 06 November 2017)

270 EXECUTIVE SUMMARY

271 PRODUCT OVERVIEW

274 PRODUCT PROFILE: DAKLINZA

288 PRODUCT PROFILE: EPCLUSA

302 PRODUCT PROFILE: HARVONI

318 PRODUCT PROFILE: MAVYRET

335 PRODUCT PROFILE: SOVALDI

347 PRODUCT PROFILE: VIEKIRA PAK FRANCHISE

365 PRODUCT PROFILE: VOSEVI

379 PRODUCT PROFILE: XIMENCY

390 PRODUCT PROFILE: ZEPATIER

406 HEPATITIS C PRICING, REIMBURSEMENT, AND ACCESS (Published on 29 August 2017)

406 EXECUTIVE SUMMARY

407 REGULATORY LABELS

416 PAYER ARCHETYPES

435 ACCESS TO RECENTLY LAUNCHED AND PIPELINE PRODUCTS

447 EVIDENTIARY REQUIREMENTS AND FUTURE PIPELINE POTENTIAL

454 US PRICING

457 US REIMBURSEMENT

483 JAPAN

487 PRICING IN THE FIVE MAJOR EU MARKETS

488 FRANCE

510 GERMANY

544 ITALY

552 SPAIN

576 UK

611 METHODOLOGY

614 PIPELINE: HEPATITIS C (Published on 06 November 2017)

614 EXECUTIVE SUMMARY

615 PIPELINE TRENDS

LIST OF FIGURES

  • 13 Figure 1: Hepatitis C - current and future market dynamics analysis
  • 14 Figure 2: Datamonitor Healthcare's drug assessment summary of key marketed brands for hepatitis C
  • 20 Figure 3: Total market sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • 22 Figure 4: Hepatitis C market value in the US, 2017-26
  • 24 Figure 5: Hepatitis C market value in Japan, 2017-26
  • 25 Figure 6: Japanese sales for GT-2 hepatitis C, by brand, 2017-26
  • 27 Figure 7: Hepatitis C sales in the five major EU markets, by country, 2017-26
  • 30 Figure 8: Total treated patient numbers for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • 32 Figure 9: Hepatitis C sales across the US, Japan, and five major EU markets, by company, 2017-26
  • 34 Figure 10: Hepatitis C sales of key brands in the US, Japan, and five major EU markets, 2017-26
  • 40 Figure 11: Patient-based forecast methodology for hepatitis C
  • 42 Figure 12: Methodology for adjusting the hepatitis C prevalent population for drug cure rates
  • 44 Figure 13: Price sources and calculations, by country
  • 57 Figure 14: Daklinza for hepatitis C - SWOT analysis
  • 58 Figure 15: Datamonitor Healthcare's drug assessment summary of Daklinza for hepatitis C
  • 59 Figure 16: Datamonitor Healthcare's drug assessment summary of Daklinza for hepatitis C
  • 61 Figure 17: Daklinza sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • 71 Figure 18: Epclusa for hepatitis C - SWOT analysis
  • 72 Figure 19: Datamonitor Healthcare's drug assessment summary of Epclusa for hepatitis C
  • 73 Figure 20: Datamonitor Healthcare's drug assessment summary of Epclusa for hepatitis C
  • 76 Figure 21: Epclusa sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • 87 Figure 22: Harvoni for hepatitis C - SWOT analysis
  • 88 Figure 23: Datamonitor Healthcare's drug assessment summary of Harvoni for hepatitis C
  • 89 Figure 24: Datamonitor Healthcare's drug assessment summary of Harvoni for hepatitis C
  • 91 Figure 25: Harvoni sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • 103 Figure 26: Mavyret for hepatitis C - SWOT analysis
  • 104 Figure 27: Datamonitor Healthcare's drug assessment summary of Mavyret for hepatitis C
  • 105 Figure 28: Datamonitor Healthcare's drug assessment summary of Mavyret for hepatitis C
  • 108 Figure 29: Mavyret sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • 117 Figure 30: Sovaldi for hepatitis C - SWOT analysis
  • 118 Figure 31: Datamonitor Healthcare's drug assessment summary of Sovaldi for hepatitis C
  • 119 Figure 32: Datamonitor Healthcare's drug assessment summary of Sovaldi for hepatitis C
  • 121 Figure 33: Sovaldi sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • 131 Figure 34: Viekira Pak franchise for hepatitis C - SWOT analysis
  • 132 Figure 35: Datamonitor Healthcare's drug assessment summary of the Viekira Pak franchise for hepatitis C
  • 133 Figure 36: Datamonitor Healthcare's drug assessment summary of the Viekira Pak franchise for hepatitis C
  • 135 Figure 37: Viekira Pak sales for hepatitis C across the US and five major EU markets, by country, 2017-26
  • 137 Figure 38: Viekira XR sales for hepatitis C in the US, 2017-26
  • 138 Figure 39: Technivie sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • 149 Figure 40: Vosevi for hepatitis C - SWOT analysis
  • 150 Figure 41: Datamonitor Healthcare's drug assessment summary of Vosevi for hepatitis C
  • 151 Figure 42: Datamonitor Healthcare's drug assessment summary of Vosevi for hepatitis C
  • 153 Figure 43: Vosevi sales for hepatitis C across the US and five major EU markets, by country, 2017-26
  • 161 Figure 44: Ximency for hepatitis C - SWOT analysis
  • 162 Figure 45: Datamonitor Healthcare's drug assessment summary of Ximency for hepatitis C
  • 163 Figure 46: Datamonitor Healthcare's drug assessment summary of Ximency for hepatitis C
  • 165 Figure 47: Ximency sales for hepatitis C in Japan, 2017-26
  • 176 Figure 48: Zepatier for hepatitis C - SWOT analysis
  • 177 Figure 49: Datamonitor Healthcare's drug assessment summary of Zepatier for hepatitis C
  • 178 Figure 50: Datamonitor Healthcare's drug assessment summary of Zepatier for hepatitis C
  • 180 Figure 51: Zepatier sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • 191 Figure 52: Percentage of chronic hepatitis C prevalent population who are diagnosed in the US, Japan, and five major EU markets, by country
  • 192 Figure 53: Percentage of the hepatitis C diagnosed population under physician care in the US, Japan, and five major EU markets, by country
  • 196 Figure 54: Prevalence of hepatitis C genotypes across the US, Japan, and five major EU markets, by country
  • 199 Figure 55: Treatment status of hepatitis C patients under specialist care in the US, Japan, and five major EU markets, by country (2017)
  • 200 Figure 56: Treatment status of hepatitis C patients under specialist care in the US, Japan, and five major EU markets, by country (2015)
  • 204 Figure 57: Breakdown of pharmacologically treated chronic hepatitis C patients in the US, Japan, and five major EU markets by line of therapy, by country
  • 214 Figure 58: Top four brands of each analyzed market used for the treatment of GT-1 first-line hepatitis C patients, by country
  • 217 Figure 59: Top five brands of each analyzed market used for the treatment of GT-1 second-line and beyond hepatitis C patients, by country
  • 219 Figure 60: Top four brands of each analyzed market used for the treatment of GT-2 first-line hepatitis C patients, by country
  • 220 Figure 61: Top four brands of each analyzed market used for the treatment of GT-2 second-line and beyond hepatitis C patients, by country
  • 222 Figure 62: Top four regimens of each analyzed market used for the treatment of GT-3 first-line hepatitis C patients, by country
  • 223 Figure 63: Top four brands of each analyzed market used for the treatment of GT-3 first-line hepatitis C patients, by country
  • 225 Figure 64: Top five brands of each analyzed market used for the treatment of GT-4 first-line hepatitis C patients, by country
  • 244 Figure 65: Methodology for adjusting hepatitis C prevalent population for drug cure rates
  • 249 Figure 66: Trends in total hepatitis C prevalent cases in the US, Japan, and five major EU markets, by country, 2016-36
  • 250 Figure 67: Absolute growth in total hepatitis C prevalent cases in the US, Japan, and five major EU markets, by country, 2016-36
  • 258 Figure 68: Trends in chronic hepatitis C prevalent cases after adjusting for treatment and cure in the US, Japan, and five major EU markets, by country, 2016-36
  • 280 Figure 69: Daklinza for hepatitis C - SWOT analysis
  • 281 Figure 70: Datamonitor Healthcare's drug assessment summary of Daklinza for hepatitis C
  • 282 Figure 71: Datamonitor Healthcare's drug assessment summary of Daklinza for hepatitis C
  • 284 Figure 72: Daklinza sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • 294 Figure 73: Epclusa for hepatitis C - SWOT analysis
  • 295 Figure 74: Datamonitor Healthcare's drug assessment summary of Epclusa for hepatitis C
  • 296 Figure 75: Datamonitor Healthcare's drug assessment summary of Epclusa for hepatitis C
  • 299 Figure 76: Epclusa sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • 310 Figure 77: Harvoni for hepatitis C - SWOT analysis
  • 311 Figure 78: Datamonitor Healthcare's drug assessment summary of Harvoni for hepatitis C
  • 312 Figure 79: Datamonitor Healthcare's drug assessment summary of Harvoni for hepatitis C
  • 314 Figure 80: Harvoni sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • 326 Figure 81: Mavyret for hepatitis C - SWOT analysis
  • 327 Figure 82: Datamonitor Healthcare's drug assessment summary of Mavyret for hepatitis C
  • 328 Figure 83: Datamonitor Healthcare's drug assessment summary of Mavyret for hepatitis C
  • 331 Figure 84: Mavyret sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • 340 Figure 85: Sovaldi for hepatitis C - SWOT analysis
  • 341 Figure 86: Datamonitor Healthcare's drug assessment summary of Sovaldi for hepatitis C
  • 342 Figure 87: Datamonitor Healthcare's drug assessment summary of Sovaldi for hepatitis C
  • 344 Figure 88: Sovaldi sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • 354 Figure 89: Viekira Pak franchise for hepatitis C - SWOT analysis
  • 355 Figure 90: Datamonitor Healthcare's drug assessment summary of the Viekira Pak franchise for hepatitis C
  • 356 Figure 91: Datamonitor Healthcare's drug assessment summary of the Viekira Pak franchise for hepatitis C
  • 358 Figure 92: Viekira Pak sales for hepatitis C across the US and five major EU markets, by country, 2017-26
  • 360 Figure 93: Viekira XR sales for hepatitis C in the US, 2017-26
  • 361 Figure 94: Technivie sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • 372 Figure 95: Vosevi for hepatitis C - SWOT analysis
  • 373 Figure 96: Datamonitor Healthcare's drug assessment summary of Vosevi for hepatitis C
  • 374 Figure 97: Datamonitor Healthcare's drug assessment summary of Vosevi for hepatitis C
  • 376 Figure 98: Vosevi sales for hepatitis C across the US and five major EU markets, by country, 2017-26
  • 384 Figure 99: Ximency for hepatitis C - SWOT analysis
  • 385 Figure 100: Datamonitor Healthcare's drug assessment summary of Ximency for hepatitis C
  • 386 Figure 101: Datamonitor Healthcare's drug assessment summary of Ximency for hepatitis C
  • 388 Figure 102: Ximency sales for hepatitis C in Japan, 2017-26
  • 399 Figure 103: Zepatier for hepatitis C - SWOT analysis
  • 400 Figure 104: Datamonitor Healthcare's drug assessment summary of Zepatier for hepatitis C
  • 401 Figure 105: Datamonitor Healthcare's drug assessment summary of Zepatier for hepatitis C
  • 403 Figure 106: Zepatier sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • 487 Figure 107: Pricing of key marketed hepatitis C drugs in the five major EU markets, by country
  • 612 Figure 108: Price sources and calculations, by country

LIST OF TABLES

  • 21 Table 1: Total market sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • 23 Table 2: Hepatitis C market value in the US ($m), 2017-26
  • 24 Table 3: Hepatitis C market value in Japan ($m), 2017-26
  • 26 Table 4: Japanese sales for GT-2 hepatitis C, by brand ($m), 2017-26
  • 28 Table 5: Hepatitis C sales in the five major EU markets, by country ($m), 2017-26
  • 31 Table 6: Total treated patient numbers for hepatitis C across the US, Japan, and five major EU markets, by country, 2017-26
  • 33 Table 7: Hepatitis C sales across the US, Japan, and five major EU markets, by company ($m), 2017-26
  • 35 Table 8: Hepatitis C sales of key brands in the US, Japan, and five major EU markets ($m), 2017-26
  • 38 Table 9: Summary of drug classes and molecules in Datamonitor Healthcare's chronic hepatitis C patient-based forecast
  • 45 Table 10: Exchange rates used for calculating prices
  • 46 Table 11: Gastroenterologists, hepatologists, and infectious disease specialists surveyed for the hepatitis C primary research study, 2017
  • 52 Table 12: Daklinza drug profile
  • 54 Table 13: Pivotal studies supporting approvals of Daklinza
  • 62 Table 14: Daklinza sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • 66 Table 15: Epclusa drug profile
  • 67 Table 16: Pivotal studies supporting approvals of Epclusa
  • 70 Table 17: Epclusa late-phase trial data in hepatitis C
  • 77 Table 18: Epclusa sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • 80 Table 19: Harvoni drug profile
  • 82 Table 20: Pivotal studies supporting approvals of Harvoni
  • 86 Table 21: Ongoing studies of Harvoni
  • 92 Table 22: Harvoni sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • 96 Table 23: Mavyret drug profile
  • 98 Table 24: Pivotal Phase III studies of Mavyret in hepatitis C
  • 101 Table 25: Other Phase III studies of Mavyret in hepatitis C
  • 102 Table 26: Mavyret ongoing Phase III trials in hepatitis C
  • 109 Table 27: Mavyret sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • 113 Table 28: Sovaldi drug profile
  • 115 Table 29: Pivotal studies supporting approvals of Sovaldi
  • 122 Table 30: Sovaldi sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • 125 Table 31: Viekira Pak franchise drug profile
  • 127 Table 32: Pivotal studies supporting approvals of the Viekira Pak franchise
  • 136 Table 33: Viekira Pak sales for hepatitis C across the US and five major EU markets, by country ($m), 2017-26
  • 137 Table 34: Viekira XR sales for hepatitis C in the US ($m), 2017-26
  • 139 Table 35: Technivie sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • 143 Table 36: Vosevi drug profile
  • 145 Table 37: Pivotal Phase III trials of Vosevi for chronic hepatitis C infection
  • 154 Table 38: Vosevi sales for hepatitis C across the US and five major EU markets, by country ($m), 2017-26
  • 157 Table 39: Ximency drug profile
  • 158 Table 40: Key Phase III studies of Ximency in hepatitis C
  • 165 Table 41: Ximency sales for hepatitis C in Japan ($m), 2017-26
  • 168 Table 42: Zepatier drug profile
  • 170 Table 43: Pivotal studies supporting approvals of Zepatier
  • 174 Table 44: Zepatier late-phase trial data in hepatitis C
  • 181 Table 45: Zepatier sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • 186 Table 46: Gastroenterologists, hepatologists, and infectious disease specialists surveyed for the hepatitis C primary research study, 2017
  • 190 Table 47: Interpretation of results from hepatitis C screening assays
  • 197 Table 48: Prevalence of hepatitis C genotypes across the US, Japan, and five major EU markets, by country
  • 198 Table 49: METAVIR fibrosis scores of patients under specialist care in the US, Japan, and five major EU markets, by country
  • 202 Table 50: Reasons for not receiving hepatitis C treatment in the US, Japan, and five major EU markets, by country
  • 207 Table 51: Treatments available for hepatitis C across the US, Japan, and five major EU markets
  • 211 Table 52: Summary of "recommended" treatment options for newly diagnosed patients in AASLD and EASL treatment guidelines
  • 229 Table 53: Relative importance of unmet needs in hepatitis C treatment in the US, Japan, and five major EU markets, by country
  • 236 Table 54: Sources used for hepatitis C analysis in the US, Japan, and five major EU markets
  • 247 Table 55: Total prevalent cases of hepatitis C in the US, Japan, and five major EU markets, by country, 2016-36
  • 251 Table 56: Age-specific total prevalent cases of hepatitis C in the US, Japan, and five major EU markets, by country, 2016
  • 252 Table 57: Gender-specific total prevalent cases of hepatitis C in the US, Japan, and five major EU markets, by country, 2016
  • 253 Table 58: Hepatitis C virus genotype distributions across the US, Japan, and five major EU markets, by country, 2016
  • 254 Table 59: Total prevalent cases of hepatitis C, by genotype, across the US, Japan, and five major EU markets, by country, 2016
  • 256 Table 60: Treatment- and cure-adjusted total prevalent cases of chronic hepatitis C in the US, Japan, and five major EU markets, by country, 2016-36
  • 263 Table 61: Validation of total chronic hepatitis C forecast estimates against benchmark estimates, by country, 2016
  • 272 Table 62: Profiled key marketed drugs for hepatitis c
  • 275 Table 63: Daklinza drug profile
  • 277 Table 64: Pivotal studies supporting approvals of Daklinza
  • 285 Table 65: Daklinza sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • 289 Table 66: Epclusa drug profile
  • 290 Table 67: Pivotal studies supporting approvals of Epclusa
  • 293 Table 68: Epclusa late-phase trial data in hepatitis C
  • 300 Table 69: Epclusa sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • 303 Table 70: Harvoni drug profile
  • 305 Table 71: Pivotal studies supporting approvals of Harvoni
  • 309 Table 72: Ongoing studies of Harvoni
  • 315 Table 73: Harvoni sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • 319 Table 74: Mavyret drug profile
  • 321 Table 75: Pivotal Phase III studies of Mavyret in hepatitis C
  • 324 Table 76: Other Phase III studies of Mavyret in hepatitis C
  • 325 Table 77: Mavyret ongoing Phase III trials in hepatitis C
  • 332 Table 78: Mavyret sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • 336 Table 79: Sovaldi drug profile
  • 338 Table 80: Pivotal studies supporting approvals of Sovaldi
  • 345 Table 81: Sovaldi sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • 348 Table 82: Viekira Pak franchise drug profile
  • 350 Table 83: Pivotal studies supporting approvals of the Viekira Pak franchise
  • 359 Table 84: Viekira Pak sales for hepatitis C across the US and five major EU markets, by country ($m), 2017-26
  • 360 Table 85: Viekira XR sales for hepatitis C in the US ($m), 2017-26
  • 362 Table 86: Technivie sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • 366 Table 87: Vosevi drug profile
  • 368 Table 88: Pivotal Phase III trials of Vosevi for chronic hepatitis C infection
  • 377 Table 89: Vosevi sales for hepatitis C across the US and five major EU markets, by country ($m), 2017-26
  • 380 Table 90: Ximency drug profile
  • 381 Table 91: Key Phase III studies of Ximency in hepatitis C
  • 388 Table 92: Ximency sales for hepatitis C in Japan ($m), 2017-26
  • 391 Table 93: Zepatier drug profile
  • 393 Table 94: Pivotal studies supporting approvals of Zepatier
  • 397 Table 95: Zepatier late-phase trial data in hepatitis C
  • 404 Table 96: Zepatier sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • 408 Table 97: Approved labels for marketed hepatitis C drugs in the US, Japan, and five major EU markets
  • 419 Table 98: Initial cost-containment measures utilized to manage the budget impact of hepatitis C drugs in the US and five major EU markets
  • 422 Table 99: Current cost-containment measures utilized to manage the budget impact of hepatitis C drugs in the US and five major EU markets
  • 429 Table 100: Levers impacting access to hepatitis C drugs in the US and five major EU markets
  • 455 Table 101: US pricing of key marketed drugs
  • 462 Table 102: Prior authorization criteria for hepatitis C agents in six major health plans
  • 467 Table 103: Formulary placement of hepatitis C agents in selected commercial formularies
  • 473 Table 104: Formulary placement of hepatitis C agents in selected 2017 Medicare Part D formularies
  • 479 Table 105: Formulary placement of hepatitis C medications in selected Medicaid state preferred drug lists
  • 484 Table 106: Pricing of key marketed hepatitis C drugs in Japan
  • 485 Table 107: Pricing of key hepatitis C drugs in Japan
  • 489 Table 108: Transparency Committee's ASMR ratings and pricing implications
  • 489 Table 109: Transparency Committee's SMR ratings and pricing implications
  • 490 Table 110: Transparency Committee's assessment of hepatitis C treatments
  • 512 Table 111: G-BA assessment of Sovaldi
  • 518 Table 112: G-BA assessment of Olysio
  • 525 Table 113: G-BA assessment of Daklinza
  • 527 Table 114: G-BA assessment of Harvoni
  • 531 Table 115: G-BA assessment of Viekirax ± Exviera
  • 535 Table 116: G-BA assessment of Epclusa
  • 539 Table 117: IQWiG assessment of Zepatier
  • 545 Table 118: AIFA's reimbursement decisions for hepatitis C agents in Italy
  • 548 Table 119: Local formulary decisions for hepatitis C agents
  • 553 Table 120: Therapeutic positioning reports for hepatitis C agents in Spain
  • 561 Table 121: Spanish Society of Hospital Pharmacy ratings
  • 562 Table 122: GENESIS-SEFH assessment of hepatitis C treatments
  • 577 Table 123: NICE assessments for hepatitis C therapies
  • 591 Table 124: SMC assessments for hepatitis C therapies
  • 613 Table 125: Exchange rates used for calculating branded drug prices

 

Back to Top